VISTIN PHARMA ASA: årsregnskap 2025 vs 2024
Shrank 100% on revenue, returned to profit, cash halved-plus
approved 2026-04-23; registry 2026-09-01; journal 2026 748965
Summary
What changed
Comparing Årsregnskap 2025 with 2024 for VISTIN PHARMA ASA. Revenue 429.50m NOK → 452.3k NOK (-99.9%). Net result -3.53m NOK → +10.99m NOK. Equity 184.03m NOK → 139.59m NOK.
On the constructive side: operating result improved; turned profitable. Pressures included: revenue fell; equity eroded; cash fell.
Also worth watching: sharp cash drawdown; paid-in equity reduced; cogs fell. All figures are taken from the published annual accounts for VISTIN PHARMA ASA.
At a glance
Scorecard
What improved
-
↑
Operating result improved
Operating result -6.05m NOK → -5.16m NOK (op. margin -1.4% → -1139.8%). Calculated
-
↑
Turned profitable
Net result flipped from a loss of 3.53m NOK to a profit of 10.99m NOK. Calculated
What deteriorated
-
↓
Revenue fell
Operating income / revenue moved from 429.50m NOK to 452.3k NOK (-99.9% YoY). Calculated
-
↓
Equity eroded
Book equity 184.03m NOK → 139.59m NOK (equity ratio 98.6% → 98.2%). Calculated
-
↓
Cash fell
Bank deposits 5.93m NOK → 1.27m NOK (-78.6% YoY). Calculated
-
↓
Payroll up without matching revenue
Salary cost 3.70m NOK → 98.52m NOK (1% → 21782% of revenue). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (5.93m NOK → 1.27m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation
-
·
Paid-in equity reduced
Paid-in equity fell 184.03m NOK → 118.21m NOK — check capital reduction, conversion, or reclassification. Interpretation
-
·
COGS fell
COGS / varekostnad 149.97m NOK → 151.5k NOK (-99.9% YoY). Calculated
-
·
Book investments changed
Investment / intangible book value 54.86m NOK → 51.41m NOK. Reported fact